Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate

Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.